Results 81 to 90 of about 6,482 (100)

CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder

Heliyon, 2021
Chihiro Namatame, Tatsuro Misu, Shuhei Nishiyama   +2 more
exaly  

Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4–immunoglobulin G–seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial

Multiple Sclerosis Journal, 2022
Mary Rensel, Aram Zabeti, Maureen A Mealy   +2 more
exaly  

Biotinidase Deficiency as a Mimic of Neuromyelitis Optica Spectrum Disorder in Childhood

JAMA Neurology, 2021
Jonathan D Santoro
exaly  

Prevalence and incidence of neuromyelitis optica spectrum disorder and multiple sclerosis in Korea

Multiple Sclerosis Journal, 2020
Jee-Eun Kim, Sanghyun Park, Kyungdo Han   +2 more
exaly  

Longitudinal follow-up of serum biomarkers in patients with neuromyelitis optica spectrum disorder

Multiple Sclerosis Journal, 2022
Hyunjin Kim, Eun-Jae Lee, Seungmi Kim
exaly  

Structural and functional hippocampal alterations in Multiple sclerosis and neuromyelitis optica spectrum disorder

Multiple Sclerosis Journal, 2022
Yuxin Li, Yunyun Duan, Guanmei Cao
exaly  

Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea

Multiple Sclerosis Journal, 2017
Jin Myoung Seok, Hye-Jin Cho, Suk-Won Ahn   +2 more
exaly  

Sexual dysfunction in patients with neuromyelitis optica spectrum disorder

Journal of Neuroimmunology, 2020
Hongxi Chen, Chao Yan, Yuhan Qiu
exaly  

Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?

Multiple Sclerosis Journal, 2012
Su-Hyun Kim, Woojun Kim
exaly  

Brain abnormalities as an initial manifestation of neuromyelitis optica spectrum disorder

Multiple Sclerosis Journal, 2011
Woojun Kim, Su-Hyun Kim
exaly